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A B S T R A C T
Background
The outcome of glaucoma surgery can be affected by the rate at which the surgical wound heals. Beta radiation has been proposed as a
rapid and simple treatment to slow down the healing response.
Objectives
To assess the effectiveness of beta radiation during glaucoma surgery (trabeculectomy).
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library (which includes the Cochrane
Eyes and Vision Group Trials Register) (Issue 4 2008), MEDLINE (January 1966 to October 2008) and EMBASE (January 1980 to
October 2008). The databases were last searched on 24 October 2008.
Selection criteria
We included randomised controlled trials comparing trabeculectomy with beta radiation to trabeculectomy without beta radiation.
Data collection and analysis
We collected data on surgical failure (intraocular pressure > 21 mmHg), intraocular pressure and adverse effects of glaucoma surgery.
We pooled data using a fixed-effect model.
Main results
We found four trials that randomised 551 people to trabeculectomy with beta irradiation versus trabeculectomy alone. Two trials were
in Caucasian people (126 people), one trial in black African people (320 people) and one trial in Chinese people (105 people). People
who had trabeculectomy with beta irradiation had a lower risk of surgical failure compared to people who had trabeculectomy alone
(pooled risk ratio (RR) 0.23 (95% CI 0.14 to 0.40). Beta irradiation was associated with an increased risk of cataract (RR 2.89, 95%
CI 1.39 to 6.0).
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Authors’ conclusions
Trabeculectomy with beta irradiation has a lower risk of surgical failure compared to trabeculectomy alone. A trial of beta irradiation
versus anti-metabolite is warranted.
P L A I N L A N G U A G E S U M M A R Y
Beta radiation in glaucoma surgery
The aim of glaucoma surgery is to lower the pressure in the eye. The outcome of glaucoma surgery can be affected by the rate at which
the surgical wound heals. Beta radiation has been proposed as a rapid and simple treatment to slow down the healing response. It is
applied during the operation using a radioactive applicator which emits beta rays which have only a very local penetration to a depth of
less than one millimetre. The intensity of the emission from the applicator (usually Strontium-90) determines the duration it is applied
to the surgical site in order to deliver the required dose of radiation which effectively prevents scar tissue formation.
We found four trials that randomised 551 people to trabeculectomy with beta irradiation versus trabeculectomy alone. People who
had trabeculectomy with beta irradiation were less likely to have a high pressure that was too high one year after surgery compared to
people who had trabeculectomy alone. However, people who had beta irradiation had an increased risk of cataract after surgery.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
beta radiation for glaucoma surgery
Patient or population: patients with glaucoma surgery
Settings: Hospitals in low, middle or high income countries
Intervention: beta radiation
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control beta radiation
Sur-
gical failure (intraocular
pressure >21mmHg)
(follow-up: 12 months)
Low risk population1 RR 0.23
(0.14 to 0.4)
561
(4)
⊕⊕⊕©
moderate2
100 per 1000 23 per 1000
(14 to 40)
High risk population1
300 per 1000 69 per 1000
(42 to 120)
Intraocular pressure
(follow-up: 12 months)
The mean intraocular
pressure in the control
groups was
13.85 mmHg
The mean Intraocular
pressure in the interven-
tion groups was
0.97 lower
(2.56 lower to 0.62
higher)
123
(2)
⊕⊕©©
low3,4
Adverse effect: cataract Medium risk population RR 1.79
(0.62 to 5.14)
423
(3)
⊕⊕⊕©
moderate5,6
50 per 1000 89 per 1000
(31 to 257)
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*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidance
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Based on control events in included studies. Higher risks of surgical failure seen in black African populations.
2 Majority of evidence from larger high quality study in black African people. However, relative risks for smaller studies in Caucasian and
Chinese people were of a similar order but imprecise (pooled relative risk 0.15 (95% CI 0.02 to 1.28).
3 Data for Caucasian patients only.
4 Two studies contributed data to this outcome, n=123 people. Pooled mean difference was -0.97 (-2.56, 0.62). i.e. beta radiation
compatible with a reduction of approximately 2.5mmHg intraocular pressure but also with an increased pressure of less than 1mmHg.
5 Barnes 2000 and Kirwan 2006 had similar estimates of the risk of cataract associated with beta irradiation of approximately 3 to 3.5.
In contrast Rehman 2002 had a relative risk reduction of 50%. However, there were small numbers of events (2 cataracts in each group)
in Rehman 2002.
6 The pooled analysis had a total of 9 events in the treatment group and 4 in the control group.
4
B
e
ta
ra
d
ia
tio
n
fo
r
g
la
u
c
o
m
a
su
rg
e
r
y
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
0
9
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
B A C K G R O U N D
Beta radiation inhibits wound healing, and has been shown to
improve survival of glaucoma filtration surgery in vitro and in vivo
(Khaw 1991). Beta radiation causes growth-arrest, primarily due
to its effects on P450 (a controller of cell cycling), rather than
producing destruction of cells (Constable 1999).
Description of the condition
The term glaucoma defines a group of conditions in which there
is characteristic optic neuropathy associated with progressive vi-
sual field loss (loss of peripheral and then central vision). Raised
intraocular pressure (IOP) is recognised to be one of the principal
risk factors for glaucoma (Buhrmann 2000; Hollows 1966; Leske
1995). Glaucoma is the commonest cause of irreversible blindness
worldwide, with at least 70 million people affected and over seven
million blind from the condition (Quigley 1996). With an ageing
world population, the prevalence is likely to increase considerably
in the coming years.
Description of the intervention
Lowering IOP has long been established as a means of treating
glaucoma, despite a lack of good data for its effectiveness in pre-
venting visual field loss (Rossetti 1993; Vass 2007). What infor-
mation we do have suggests that surgery is currently the most ef-
fective means of lowering IOP (Burr 2004; Migdal 1986, Lichter
2001). Trabeculectomy is the most widely used surgical procedure
for glaucoma. In the developed world, surgery is used where other
modalities (medical or laser therapy or both) are not sufficiently
effective. In poorer countries trabeculectomy may be used as a pri-
mary treatment for glaucoma.
The aim of the trabeculectomy operation is to create a fistula
(channel) between the anterior chamber and the subconjunctival
space to allow controlled release of fluid from the eye. A partial-
thickness scleral flap is fashioned at the limbus, with a sclerostomy
created under this flap forming a so-called guarded fistula. Fluid
from the anterior chamber drains out of the eye through this fistula
to the subconjunctival space forming a conjunctival bleb. Fluid
in this bleb is thought to be carried away by vessels within the
conjunctiva and also by passing through the conjunctival wall.
Final IOP may be determined by the size of the bleb, downstream
drainage from the conjunctival vessels and the healing response of
the eye. The most common cause for failure of trabeculectomy is
subconjunctival fibrosis (Hitchings 1983) resulting in occlusion
of the fistula with loss of IOP lowering effect.
In elderly white people with glaucoma who have not had prior
eye surgery, the success rate of surgery is considered to be in the
region of 80%. However, the success rate is lower in certain groups
including black people, people with ocular inflammation or neo-
vascularisation, those who have had previous ocular surgery and
children (Ritch 1996). It is also apparent that prior topical medical
treatment may prejudice the overall success of surgery (Broadway
1994; Lavin 1990).
Various agents have been used to reduce the excessive healing that
leads to failure of trabeculectomy. Themost widely used agents are
MitomycinC and 5-Fluorouracil.MitomycinCwas introduced in
1983 although widespread use did not occur until themid 1990s (
Chen 1983). 5-Fluorouracil was introduced in 1984, after positive
reports from a randomised controlled trial (RCT), and was used
widely until use ofMitomycin C became widespread (FFSG 1996;
Heuer 1984; Singh 2000). Systematic reviews of postoperative 5-
Fluorouracil (Wormald 2001) and of intraoperative Mitomycin C
(Wilkins 2005) are already published in The Cochrane Library.
Although both of these antimetabolites have proven effective clin-
ically they are associated with complications. Both Mitomycin C
and 5-Fluorouracil are used in liquid form, delivered by placing
microsurgical sponges soaked in the drug directly onto the opera-
tive site. Because the antimetabolites are liquids they carry the risk
of leakage away from the treatment site. This leakage can lead to
extraocular or, more seriously, intraocular toxicity (Franks 1991).
Furthermore, the variability of the delivery of the drug between
the impregnated sponge and the subconjunctival tissues means
that accurate dosimetry has proven difficult. Both treatments have
been associated with the development of thin, avascular filtration
blebs, and these are in turn associated with an increased risk of
sight threatening complications including hypotony (a very soft
eye) and endophthalmitis (ocular infection) (Wolner 1991; Yaldo
1993; Zacharia 1993).
One alternative to the use of antimetabolites is beta radiation.
Precise control of dose and area of treatmentmay be easily achieved
as it is applied using a Strontium-90 applicator at the completion
of surgery. The doses used are typically 750 cGy or 1000 cGy and
single application is used without fractionation. Beta radiation
was first used for glaucoma surgery in the 1940s (Iliff 1944) and
has been used at Moorfields Eye Hospital for many years in the
management of paediatric glaucoma. Good results were reported
with a non-randomised retrospective study in a cohort of these
patients (Miller 1991). Beta radiation may be especially suitable
for use in developing countries due to the technical simplicity of
application and as no running costs are required.
Why it is important to do this review
Recently, several workers have described the use of beta radiation
with trabeculectomy. The overall effectiveness of this mode of
therapy is unknown and a systematic review is needed to assess the
effects both in people where a high success rate is expected and in
those where a lower success rate would be expected.
O B J E C T I V E S
5Beta radiation for glaucoma surgery (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The aims of this review were to assess the effects of beta radia-
tion with trabeculectomy on surgical failure due to postoperative
scarring in people with glaucoma. Mean IOP was an additional
primary outcome. The review also aimed to gather evidence on
whether beta radiation is associated with increased complications
after surgery as compared to standard trabeculectomy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials of acceptable quality.
Types of participants
We included trials in which participants were people with glau-
coma undergoing trabeculectomy. All glaucoma diagnosis cate-
gories were included. We included people undergoing a first surgi-
cal procedure without any perceived risk factors for surgical failure
and people who were considered to have a high risk of surgical
failure. We did not include people undergoing simultaneous bi-
lateral surgery.
Types of interventions
We included trials in which trabeculectomy with beta radiation
applied at any dose was compared to trabeculectomy alone, with
placebo or with another anti-scarring agent. We excluded trials in
which trabeculectomy was combined with cataract extraction.
Types of outcome measures
Primary outcomes
The primary outcome measures for this review were:
1. the proportion of failed trabeculectomies at 12 months or more
after surgery (defined as repeat surgery or uncontrolled IOP more
than 20 mmHg with or without additional topical or systemic
medications);
2. mean IOP at 12 months or more. Intraocular pressure is used as
a primary outcome measure for many clinical trials in glaucoma.
The ideal outcome measure is visual function, most commonly
expressed in terms of visual field (with allowance for visual acuity).
However, the difficulty in determining visual field progression due
to the inherently high noise in this psychophysical measure means
that trials using this outcome measure need to be performed with
large sample sizes and long follow-up time. For practical reasons,
IOP was used as a surrogate measurement; the degree of IOP
reduction appears to be related to the rate of visual field progression
(Gaasterland 2000).
Secondary outcomes
Secondary outcome measures included:
3. adverse effects including;
a. visual loss,
b. wound leaks: the presence of a positive Seidel test (visible aque-
ous flow with the tear film stained with fluorescein),
c. late endophthalmitis - an infection of the globe contents that
even with prompt aggressive treatment often results in substan-
tial loss of visual function. ’Late’ here implies infection arising
from organisms gaining access to the globe through thin walled
drainage blebs or frank breaks in the conjunctival epithelium after
the immediate postoperative period when infectious agents may
have entered the eye during the surgical procedure,
d. hypotony: the IOP is below five millimetres mercury and/or
associated with complications such as macular oedema and sight
loss or choroidal detachments,
e. cataract: the subsequent development of visually significant
cataract.
4. outcomes relating to quality of life or patient’s perspective of
care;
5. data relevant to economic evaluation.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vision
Group Trials Register) (The Cochrane Library, Issue 4, 2008),
MEDLINE (January 1960 to October 2008) and EMBASE (Jan-
uary 1980 to October 2008). There were no language or date re-
strictions in the search for trials. All databases were last searched
on 24 October 2008.
See: Appendices for details of search strategies for CENTRAL
(Appendix 1),MEDLINE (Appendix 2) andEMBASE (Appendix
3).
Searching other resources
We manually searched the Association for Research in Vision and
Ophthalmology (ARVO) abstract books from 1990 using a key-
word index search for relevant studies. Keywords used were: radi-
ation; beta radiation; strontium. All studies with these words in
the permuted index were examined to see if they were relevant.
We contacted researchers who are active in the field and manu-
facturers of the emitter for information on further published or
unpublished studies.
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Data collection and analysis
Selection of studies
Two authors independently screened the titles and abstracts ob-
tained by the searches and full copies of definitely or potentially
relevant studies were obtained. Where the trial had not been fully
reported, or was unreported, we attempted to contact the investi-
gators and endeavour to obtain as much relevant data as possible.
Details of the trial were not masked during the assessment.
Assessment of risk of bias in included studies
Relevant details about study design were extracted independently
by two authors. Risk of bias was assessed using the Cochrane
Collaboration’s tool for assessing risk of bias which is a domain-
based evaluation (Higgins 2008). We contacted study authors for
further information on any item graded as unclear.
Data synthesis
For description of dichotomous data such as failure rates, a sum-
mary odds ratio was calculated. For IOP, the weighted mean dif-
ference was reported. As there were three studies or less to be com-
bined, we used a fixed-effect model. If further trials are included in
future updates of this review we will use a random-effects model.
There were not enough published studies to investigate potential
publication bias nor to conduct sensitivity analyses as planned in
the protocol (excluding poorer quality studies).
Subgroup analysis and investigation of heterogeneity
No subgroup analyses were planned in the protocol. The included
trials were conducted in different populations (black African, Cau-
casian and Chinese). There is some evidence that people of African
origin have a higher risk of surgical failure (AGIS 2001). In the
included trials there was some evidence that the control group risk
of failure of surgery was different in different ethnic groups (see
Table 1).We therefore did a (posthoc) subgroup analysis by ethnic
group.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The electronic searches identified 1180 references.
Included studies
See Table 1 and ’Characteristics of included studies’ for further
details. Four trials were found (Barnes 2000; Lai 1994; Rehman
2002; Kirwan 2006). Two trials (Barnes 2000; Rehman 2002)
were performed in Caucasian people, with primary open angle
glaucoma with an expected high success rate. Lai 1994 was found
in abstract form, which had been performed in Chinese people
with open angle glaucoma. The success rate in this trial was also
expected to be high, although not as high as for Caucasian people.
One trial was performed in black African patients (Kirwan 2006).
Two trials used a dosage of 750 cGy (Barnes 2000; Rehman 2002)
and two trials used a dosage of 1000 cGy (Kirwan 2006; Lai 1994).
A total of 551 people were randomised in these four trials. Follow-
up ranged from 12 months (Rehman 2002) to four years (Kirwan
2006).
Excluded studies
See Characteristics of excluded studies for details.
Risk of bias in included studies
See Figure 1 and Figure 2. The trials reported as research papers
were of acceptable methodological quality (Barnes 2000; Kirwan
2006; Rehman 2002). In all three trials, sealed envelopes with a
randomised number sequence were used for allocation conceal-
ment. Examiners determining outcome were unaware of trial allo-
cation. The study published in abstract form has not been subse-
quently published but we were able to get some information from
the trial investigator who reported adequate allocation conceal-
ment. Intention-to-treat analysis was not formally reported in any
trial. In all trials, only one eye was entered into the trial.
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Figure 1. Methodological quality summary: review authors’ judgements about each methodological quality
item for each included study.
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Figure 2. Methodological quality graph: review authors’ judgements about each methodological quality
item presented as percentages across all included studies.
Effects of interventions
See: Summary of findings for the main comparison
People who had trabeculectomy with beta irradiation had a lower
risk of surgical failure one year after surgery compared to people
who had trabeculectomy alone (Analysis 1.1 pooled risk ratio 0.23
(95% confidence interval (CI) 0.14 to 0.40)). The treatment ef-
fect appeared to be similar in the different ethnic groups. However
the three trials in non African people were smaller and the risk of
surgical failure lower in Caucasian people. In the two trials of Cau-
casian people there were no cases of surgical failure in the treat-
ment group. This analysis, therefore, does not have good power to
detect true differences in treatment effect in the different ethnic
groups. Only two trials reported mean IOP at the end of the study
(Analysis 2.1). People receiving beta irradiation had on average 1
mmHg lower IOP 12 months after surgery. However, this result
was not statistically significant and the result is compatible with
both lower and higher IOP after surgery (pooled mean difference
-0.97 95% CI -2.56 to 0.62).
The most recent study conducted on a South African population
was the largest with the greatest power to detect a difference in
which the relative risk of failure was reduced by 0.21 (0.11 to 0.40)
at one year Kirwan 2006.
The two trials reporting results in Caucasians both had very high
success rates. The study from New Zealand, Barnes 2000 showed
a small trend for people having beta radiation to have a higher
success rate, a lower IOP and a larger drop in IOP. None of these
results were significant. The study from Leeds, Rehman 2002 had
success rates of 95% and 100% in each arm of the trial for the
most generous definition of success and high success rates, even
for more stringent definitions. There was no significant difference
in success rates between the two arms of the trial for any outcome
measure. Neither study had sufficient power to compare adverse
effect rates.
The Hong Kong study, Lai 1994 demonstrated a significant dif-
ference in success between the two arms of the study. The failure
rate was 25% in the control arm and 9% in the treatment arm.
Adverse effects were reported in all studies but numbers were low.
There was evidence of an increased risk of cataract requiring sur-
gical intervention in the treatment group (Analysis 3.1 pooled risk
ratio 2.89 (95% CI 1.39 to 6.00)) . Numbers of other complica-
tions were too low to comment on (Analysis 3.2; Analysis 3.3),
although there was a suggestion that beta radiation augmented
trabeculectomy was associated with a small increase in the risk of
ocular hypotony (Analysis 3.2).
D I S C U S S I O N
Several points are worthy of comment in considering the data. In
the Barnes 2000 study, four participants had only three months
follow-up. We were able to obtain the raw data from the investi-
gators. One of those four participants had failed surgery with an
IOP 21mmHg or more at three months. We have counted this
patient as a surgical failure at 12 months as well. For the other
three patients who had an IOP less than 21mmHg at threemonths
we cannot make any assumptions about their status at 12 months.
The dose used for both the Rehman 2002 and Barnes 2000 studies
was 750 cGy, this is less than the dose used in Lai 1994 and cell
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culture and in vivo animal data suggests that the difference may
be a biologically significant one. In the Lai study, the numbers
were reported as percentages only and no further information was
obtained from the study author.
From the limited data available, it appears that beta radiation im-
proves success rates in people with an intermediate surgical prog-
nosis and possibly in those with an already good surgical progno-
sis. This may be at the cost of an increased rate of cataract devel-
opment.
The degree of improvement in success is similar to that of other
antimetabolites but there is no trial data comparing beta radiation
with other metabolites such as Mitomycin C or 5-Fluorouracil.
In a developing world setting, with a high surgical volume, beta
radiation has advantages in that there are no ongoing costs and it
has a long service life (more than 20 years) although capital outlay
is significant (approximately £5000 to purchase a Sr90 emitter in
the UK). A further issue is that in the UK and many other coun-
tries, a government licence is required to use a radioactive device.
Obtaining this may necessitate extra training; this and associated
bureaucracy may place a barrier on the use of an emitter. In the
UK, storage is in a lead lined repository, usually in the medical
physics department. However, this may be excessive given the at-
tenuation of Sr90 in air and storage in an area with a significant
physical distance from those in the working environment is con-
sidered to be adequate in many settings.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Beta radiation-augmented trabeculectomy reduces the risk of sur-
gical failure compared to standard trabeculectomy. It may be clin-
ically useful but it is unknown how it compares in both effective-
ness and safety to other, more widely used antimetabolites. Data
on adverse effects are limited. A specific role for beta radiation is
unclear and this depends on there being more evidence available
to guide practice.
Implications for research
There are only four trials of beta radiation for increasing the prob-
ability of success in trabeculectomy.Much of the existing evidence
for controlling wound healing after trabeculectomy concentrates
on liquid antimetabolites. How beta radiation compares to liquid
antimetabolites is unknown. Beta radiation may be particularly
useful in a developing world setting but this has yet to be evalu-
ated. Outcomes of particular interest are the degree of IOP low-
ering, success rates in the long term, and adverse effects - partic-
ularly cataract. Further trials comparing beta radiation with other
antimetabolites would be useful in such a setting but may also be
of relevance to richer countries.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Barnes 2000
Methods sealed envelopes, randomised number sequence, 3 lost to FU
Participants Caucasian > 45
Interventions trabeculectomy +/- beta radiation
Outcomes IOP < 21 = success (+/- medication) mean IOP
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “The patients randomly received or did not
receive a dose of beta radiation” Page 259,
last paragraph
Blinding?
All outcomes
Yes “There was no record of beta radiation
treatment in the patient notes, so at fol-
low up the examining doctor did not know
which arm of the study the patient be-
longed to” Bottom of page 259 top of page
260
We have made the assumption that the pa-
tient did not know either although this was
not explicitly stated
Incomplete outcome data addressed?
All outcomes
Unclear “...follow-up periods ranged between 3 and
42 months. Three patients only had 3
months follow-up..” Page 261, first para-
graph
However, follow-up times for each treat-
ment group were not given
Free of selective reporting? Yes The main outcome reported in this study
was intraocular pressure, as would be ex-
pected
Free of other bias? Yes
13Beta radiation for glaucoma surgery (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Kirwan 2006
Methods opaque sealed envelopes, envelopes opened immediately before administration of treat-
ment or placebo during surgery random number sequence with masking of allocation
by outside agency, no exclusions, 30% lost to follow up
Participants Africans > 40
Interventions trabeculectomy + beta radiation or dummy application
Outcomes IOP < 21 without medication
Notes Risk of bias assessment made on Kirwan et al. BMJ, doi:10.1136/bmj.38971.395301.7C
(published 5 October 2006)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “Randomisationwas in blocks of 20.. ”First
sentence, page 2.
Allocation concealment? Yes “... with the assigned groups distributed to
each centre in opaque, sealed envelopes.
Each participant was allocated a trial num-
ber on recruitment. The envelope with that
number was opened during surgery to de-
termine allocation” Page 2, first paragraph.
Blinding?
All outcomes
Yes “Each centre had two applicators, one ac-
tive and one placebo. The identity of the
active applicatorwas only known to IMand
SC, neither of whom participated in data
collection”.Pages 1&2, last sentence on page
1.
“Separate record sheets were used at follow-
up to mask clinicians from the treatment
allocation” Page 2, first paragraph.
Incomplete outcome data addressed?
All outcomes
Yes “Twenty participants (6%) dropped out of
the study after surgery. Some evidence was
found that the probability of not being seen
was associatedwith sex (women10% vmen
4%: P = 0.03), blindness in the fellow eye
(9% v 3%: P = 0.02), and centre (Bloem-
fontein 2%, Edendale 9%, Pretoria 3%: P
= 0.09; table 1). No strong evidence was
found for an association with other vari-
ables. A further 68 patients were lost to fol-
low-up before 12 months (36 in the radi-
ation arm). Similar mean numbers of fol-
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Kirwan 2006 (Continued)
low-up visits were completed in each of the
treatment groups (4.9 radiation group; 4.5
placebo group; P = 0.35). Participants who
were followed up showed similar distribu-
tions for socio-demographic, ophthalmic,
and surgical factors in the treatment arms
(table 1).” Page 2 first paragraph
From figure 1:
117/156 (75%) in control group followed
at 12 months; 115/164 (70%) of radiation
group followed at 12 months
Free of selective reporting? Yes All outcomes specified in the protocol were
reported in the paper. Jim Kirwan
Free of other bias? Yes
Lai 1994
Methods sealed envelopes, randomised number sequence, ? exclusions ? FU
Participants Hong Kong Chinese > 30
Interventions trabeculectomy +/- beta radiation
Outcomes IOP < 21 = success (+/- medication) mean IOP
Notes published in abstract form only
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear “Patients with primary open angle glaucoma
whose pressure was over 21 mmHg on maxi-
mum anti-glaucoma medications were assigned
randomly to eitherGroup1): Trabeculectomy, or
Group 2) Trabeculectomy + Intraoperative beta
irradiation.”
Allocation concealment? Yes
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Rehman 2002
Methods random number table, no exclusions, no loss to FU
Participants Caucasian > 40
Interventions trabeculectomy +/- beta radiation
Outcomes IOP < 21 = success (+/- medication) mean IOP
Notes recruitment terminated early due to changes in clinical practice
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes “A random numbers table was used to as-
sign each eye to either control or beta ir-
radiation group,?” Page 303, materials and
methods, first paragraph, last sentence.
Allocation concealment? Yes “..
.with ophthalmologist and patient masked
to the assignment.” Page 303, materials and
methods, first paragraph, last sentence.
Given this statement allocation conceal-
ment likely.
Blinding?
All outcomes
Yes “Patients in the control group received an
identical applicator but without an active
source (an inactive plaque also designed
by Amersham). “ Page 303, materials and
methods, middle of 3rd paragraph.
There is not much information on blind-
ing but given this statement it would be
unlikely that patients and outcome asses-
sors would know which had received beta-
radiation.
Incomplete outcome data addressed?
All outcomes
Yes No exclusions and no attrition reported.
61 patients were enrolled into the trial and
data on 61 patients reported at 12 months
for all outcomes (100% follow-up)
Free of selective reporting? Yes The main outcome reported in this study
was intraocular pressure. This is as would
be expected and in any case there were no
statistically significant differences between
the groups with respect to this outcome.
16Beta radiation for glaucoma surgery (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rehman 2002 (Continued)
Free of other bias? Yes Early termination of patient recruitment
was reported because patient recruitment
was slow. However, this early termination
was not determined by the results of the
study
FU: follow up
IOP: intraocular pressure
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Tesha 2002 Further report of data in Rehman’s study in abstract form
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D A T A A N D A N A L Y S E S
Comparison 1. Surgical failure
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 IOP > 21 mmHg 12 months or
more after surgery
4 RR (Fixed, 95% CI) 0.23 [0.14, 0.40]
1.1 Black African people 1 RR (Fixed, 95% CI) 0.21 [0.11, 0.40]
1.2 Caucasian people 2 RR (Fixed, 95% CI) 0.15 [0.02, 1.28]
1.3 Chinese people 1 RR (Fixed, 95% CI) 0.34 [0.12, 0.96]
Comparison 2. Intraocular pressure (IOP)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Mean IOP 12 months or more
after surgery
2 123 Mean Difference (IV, Fixed, 95% CI) -0.97 [-2.56, 0.62]
Comparison 3. Adverse effects
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Cataract 2 362 Risk Ratio (M-H, Fixed, 95% CI) 2.89 [1.39, 6.00]
2 Hypotony 3 423 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.62, 5.14]
3 Bleb leak 2 123 Odds Ratio (M-H, Fixed, 95% CI) 0.53 [0.12, 2.38]
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Analysis 1.1. Comparison 1 Surgical failure, Outcome 1 IOP > 21 mmHg 12 months or more after surgery.
Review: Beta radiation for glaucoma surgery
Comparison: 1 Surgical failure
Outcome: 1 IOP > 21 mmHg 12 months or more after surgery
Study or subgroup log [RR] RR Weight RR
(SE) IV,Fixed,95% CI IV,Fixed,95% CI
1 Black African people
Kirwan 2006 -1.5606 (0.3293) 67.6 % 0.21 [ 0.11, 0.40 ]
Subtotal (95% CI) 67.6 % 0.21 [ 0.11, 0.40 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.74 (P < 0.00001)
2 Caucasian people
Barnes 2000 -2.0402 (1.4525) 3.5 % 0.13 [ 0.01, 2.24 ]
Rehman 2002 -1.6607 (1.6156) 2.8 % 0.19 [ 0.01, 4.51 ]
Subtotal (95% CI) 6.3 % 0.15 [ 0.02, 1.28 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.86); I2 =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
3 Chinese people
Lai 1994 -1.0788 (0.5305) 26.1 % 0.34 [ 0.12, 0.96 ]
Subtotal (95% CI) 26.1 % 0.34 [ 0.12, 0.96 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.03 (P = 0.042)
Total (95% CI) 100.0 % 0.23 [ 0.14, 0.40 ]
Heterogeneity: Chi2 = 0.78, df = 3 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 5.37 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.75, df = 2 (P = 0.69), I2 =0.0%
0.01 0.1 1 10 100
Favours treatment Favours control
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Analysis 2.1. Comparison 2 Intraocular pressure (IOP), Outcome 1 Mean IOP 12 months or more after
surgery.
Review: Beta radiation for glaucoma surgery
Comparison: 2 Intraocular pressure (IOP)
Outcome: 1 Mean IOP 12 months or more after surgery
Study or subgroup Treatment Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Barnes 2000 29 12.1 (4.37) 33 13.85 (4.2) 55.2 % -1.75 [ -3.89, 0.39 ]
Rehman 2002 39 13 (4.8) 22 13 (4.4) 44.8 % 0.0 [ -2.38, 2.38 ]
Total (95% CI) 68 55 100.0 % -0.97 [ -2.56, 0.62 ]
Heterogeneity: Chi2 = 1.15, df = 1 (P = 0.28); I2 =13%
Test for overall effect: Z = 1.19 (P = 0.23)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours treatment Favours control
Analysis 3.1. Comparison 3 Adverse effects, Outcome 1 Cataract.
Review: Beta radiation for glaucoma surgery
Comparison: 3 Adverse effects
Outcome: 1 Cataract
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barnes 2000 7/29 4/33 42.6 % 1.99 [ 0.65, 6.12 ]
Kirwan 2006 18/151 5/149 57.4 % 3.55 [ 1.35, 9.32 ]
Total (95% CI) 180 182 100.0 % 2.89 [ 1.39, 6.00 ]
Total events: 25 (Treatment), 9 (Control)
Heterogeneity: Chi2 = 0.60, df = 1 (P = 0.44); I2 =0.0%
Test for overall effect: Z = 2.84 (P = 0.0045)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 3.2. Comparison 3 Adverse effects, Outcome 2 Hypotony.
Review: Beta radiation for glaucoma surgery
Comparison: 3 Adverse effects
Outcome: 2 Hypotony
Study or subgroup Treatment Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barnes 2000 1/29 0/33 9.3 % 3.40 [ 0.14, 80.36 ]
Kirwan 2006 6/151 2/149 40.0 % 2.96 [ 0.61, 14.43 ]
Rehman 2002 2/39 2/22 50.7 % 0.56 [ 0.09, 3.73 ]
Total (95% CI) 219 204 100.0 % 1.79 [ 0.62, 5.14 ]
Total events: 9 (Treatment), 4 (Control)
Heterogeneity: Chi2 = 1.98, df = 2 (P = 0.37); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 3.3. Comparison 3 Adverse effects, Outcome 3 Bleb leak.
Review: Beta radiation for glaucoma surgery
Comparison: 3 Adverse effects
Outcome: 3 Bleb leak
Study or subgroup Treatment Control Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Barnes 2000 0/29 2/33 49.4 % 0.21 [ 0.01, 4.64 ]
Rehman 2002 3/39 2/22 50.6 % 0.83 [ 0.13, 5.41 ]
Total (95% CI) 68 55 100.0 % 0.53 [ 0.12, 2.38 ]
Total events: 3 (Treatment), 4 (Control)
Heterogeneity: Chi2 = 0.56, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 0.83 (P = 0.40)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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A D D I T I O N A L T A B L E S
Table 1. Summary of trial characteristics
Study Ethnic group Dose N treatment group N control group Surgical failure at 12 months in control
group
Barnes 2000 Caucasian 750 cGy 31 34 12%
Kirwan 2006 Black African 1000 cGy 164 156 30%
Lai 1994 Chinese 1000 cGy 46 59 26%
Rehman 2002 Caucasian 750 cGy 39 22 14%
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Glaucoma
#2 MeSH descriptor Filtering Surgery
#3 (glaucoma* or filter* or filtrat*) near (surg*)
#4 MeSH descriptor Trabeculectomy
#5 trabeculectom*
#6 (#1 OR #2 OR #3 OR #4 OR #5)
#7 MeSH descriptor Beta Rays
#8 MeSH descriptor Radiation
#9 MeSH descriptor Strontium
#10 MeSH descriptor Brachytherapy
#11 radiat* or irradiat*
#12 strontium or SR 90
#13 beta-rad* or beta irrad*
#14 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13)
#15 (#6 AND #14)
Appendix 2. MEDLINE search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
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12. 8 not 11
13. exp glaucoma/
14. exp filtering surgery/
15. ((glaucoma$ or filter$ or filtrat$) adj3 surg$).tw.
16. exp trabeculectomy/
17. trabeculectom$.tw.
18. or/13-17
19. exp beta rays/
20. exp radiation/
21. exp strontium/
22. exp brachytherapy/
23. (radiat$ or irradiat$).tw.
24. (strontium$ or SR 90).tw.
25. (beta-radiat$ or beta-irradiat$).tw.
26. or/19-25
27. 18 and 26
28. 12 and 27
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville et al (Glanville 2006).
Appendix 3. EMBASE search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
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33. exp glaucoma/
34. exp glaucoma surgery/
35. ((glaucoma$ or filter$ or filtrat$) adj3 surg$).tw.
36. exp trabeculectomy/
37. trabeculectom$.tw.
38. or/33-37
39. exp beta radiation/
40. exp radiation/
41. exp irradiation/
42. exp strontium 90/
43. exp brachytherapy/
44. (radiat$ or irradiat$).tw.
45. (strontium$ or SR 90).tw.
46. (beta-radiat$ or beta-irradiat$).tw.
47. or/39-46
48. 38 and 47
49. 32 and 48
H I S T O R Y
Protocol first published: Issue 1, 2002
Review first published: Issue 2, 2009
Date Event Description
17 March 2008 Amended Converted to new review format.
C O N T R I B U T I O N S O F A U T H O R S
JK wrote the protocol and assessed studies for inclusion, assessed studies for risk of bias, analysed the results and wrote the text of the
review. CR assessed studies for inclusion and risk of bias and helped draft the review. JE assessed studies for risk of bias, extracted and
entered data, did the summary of findings table and edited the text of the review.
D E C L A R A T I O N S O F I N T E R E S T
One of the review authors (JFK) has conducted an RCT into the effects of beta radiation on augmenting the success of glaucoma
surgery in Africans in South Africa.
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S O U R C E S O F S U P P O R T
Internal sources
• Institute of Ophthalmology, UK.
External sources
• No sources of support supplied
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Analysis by ethnic group conducted in the review but not specified in the protocol.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Trabeculectomy [methods]; Beta Particles [adverse effects; ∗therapeutic use]; Cataract [etiology]; Combined Modality Therapy [meth-
ods]; Glaucoma [∗surgery]; Randomized Controlled Trials as Topic; Treatment Outcome; Wound Healing [∗radiation effects]
MeSH check words
Humans
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